Skip to main content

Table 4 Studies on cell and animal models demonstrating therapeutic benefit of tau reduction

From: A walk through tau therapeutic strategies

MODEL BENEFITS REFERENCES
Tet-repression of Tg-tau expression in rTg4510 mice Reduced neuronal loss and improved memory function [282]
hAPP tau−/− crosses Blocks Aß and excitotoxin mediated neuronal dysfunction [275]
hAPP (APP23) Dtau or tau−/− crosses Prevention of Aß-mediated memory deficits and improved survival [152]
CSF delivered ASOs Reduces evoked seizures in adult nTg mice [81]
tau−/− Kcna−/− crosses Reduced network hyperexcitability in mouse and Drosophila epilepsy models [141]
Crossing tau−/− mice with nTg mice Reduces learning and memory deficits due to mild repetitive traumatic brain injury in mice [57]
Streptozotocin-treated tau−/− and nTg mice Mitigates cognitive deficits in type-1 diabetes mouse model [1]
tau−/− Scn1a −/− R1407X loss-of-function truncation mice Prevents seizure and improves survival in Dravet syndrome mouse model [112]
shRNA knockdown of Mapt in nTg mouse primary neurons Prevents Aß-induced axonal transport deficits [341]
ASO knockdown of Tg-tau overexpression in PS19 mice Reduced tau pathology, reversal of existing tau pathology. Prevention of neuronal loss. Improved behavioural deficits [82]
Inducible tau knockdown in APP/PS1 x rTg4510 mice Prevents tau pathology and neuronal death in presence of Aß pathology [80]
  1. Abbreviations: Tg transgenic, nTg non-transgenic (wild-type), Tet tetracycline, hAPP human amyloid precursor protein, shRNA short hairpin RNA